Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, J; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, M; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; Moos, R von; Zaman, K; Goldhirsch, A; Swiss Group for Clinical Cancer Research (SAKK) (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Annals of Oncology, 28(2):305-312.
Pagani, O; Gelber, S; Simoncini, E; Castiglione-Gertsch, M; Price, K N; Gelber, R D; Holmberg, S B; Crivellari, D; Collins, J; Lindtner, J; Thürlimann, B; Fey, M F; Murray, E; Forbes, J F; Coates, A S; Goldhirsch, A (2009). Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Research and Treatment, 116(3):491-500.
Regan, M M; Pagani, O; Walley, B; et al; Stahel, R A (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of Oncology, 19(7):1231-1241.
Pestalozzi, B C; Zahrieh, D; Price, K N; Holmberg, S B; Lindtner, J; Collins, J; Crivellari, D; Fey, M F; Murray, E; Pagani, O; Simoncini, E; Castiglione-Gertsch, M; Gelber, R D; Coates, A S; Goldhirsch, A (2006). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of Oncology, 17(6):935-944.
Pichert, G; Bolliger, B; Buser, K; Pagani, O; Swiss Institute for Applied Cancer Research Network for Cancer P (2003). Evidence-based management options for women at increased breast/ovarian cancer risk. Annals of Oncology, 14(1):9-19.